Roche Holding AG Bearer Shares RO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
-
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
-
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
-
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
-
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
-
Roche launches newborn screening test for three severe genetic conditions
-
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
-
Roche Halts Development of Obesity Drug Candidate
Trading Information
- Previous Close Price
- CHF 358.80
- Day Range
- CHF 353.80–360.00
- 52-Week Range
- CHF 270.80–383.00
- Bid/Ask
- CHF 353.00 / CHF 371.00
- Shares Outstanding
- 796.77M
- Market Cap
- CHF 283.49B
- Volume/Avg
- 21,846 / 26,263
Key Statistics
- Price/Earnings (Normalized)
- 19.99
- Price/Sales
- 4.59
- Dividend Yield (Trailing)
- 2.75%
- Dividend Yield (Forward)
- 2.75%
- Dividend Payment Schedule
- Mar
- Total Yield
- 2.75%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 112,774
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.99 | 44.80 | 23.91 |
Price/Book Value | 8.74 | 8.47 | — |
Price/Sales | 4.59 | 5.36 | 7.16 |
Price/Cash Flow | 14.37 | 16.10 | 19.73 |
Price/Earnings
RO
MRK
ABBV
Financial Strength
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.71 | 0.49 |
Current Ratio | 1.23 | 1.32 | 0.81 |
Interest Coverage | 13.49 | 4.28 | 3.89 |
Quick Ratio
RO
MRK
ABBV
Profitability
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 6.27% | 14.29% |
Return on Equity (Normalized) | 48.77% | 16.68% | — |
Return on Invested Capital (Normalized) | 23.90% | 9.82% | 32.02% |
Return on Assets
RO
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|><>Qh!Dt | LOCK|@Q | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|N?bhXp | LOCK|?? | $617B | |||
| AbbVie Inc
ABBV
| LOCK|<W^J>@ | LOCK|<t< | $464B | |||
| Merck & Co Inc
MRK
| LOCK|by>x$Rn | LOCK|<Q | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|FL^Mc$$? | LOCK|FXt | $333B | |||
| Novartis AG ADR
NVS
| LOCK|x%WYkrB | LOCK|hS | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|%q#!ysXq | LOCK|sc | $243B | |||
| Amgen Inc
AMGN
| LOCK|!^!&&N$ | LOCK|tN% | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|>!!z>Gt | LOCK|@^v | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|>By@Tr% | LOCK|gbw | $165B |
United States